Drug
Iparomlimab/Tuvonralimab clinical trials
Also written QL1706 and PSB205.
Keep track of what changes. Save the Iparomlimab/Tuvonralimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
97 studies that test it; most in 2025 (54)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 7 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 54 |
| 2026 | 24 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 77
Qilu Pharmaceutical Co., Ltd. (19) · Sun Yat-sen University (6) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (6) · Tianjin Medical University Cancer Institute and Hospital (5) · Hebei Medical University Fourth Hospital (4) · Peking University Cancer Hospital & Institute (3) · The First Affiliated Hospital with Nanjing Medical University (3) · Fudan University (3)
Often tested with
Tested in the same studies.
Bevacizumab (7) · Lenvatinib (6) · Albumin-Bound Paclitaxel (3) · Paclitaxel (3) · Cisplatin (3) · Carboplatin (2) · Xelox (2) · Olaparib (2)
Studies
Open first, then newest update. How each study uses Iparomlimab/Tuvonralimab is read from its arms, and is right about nine times in ten.
Testing it · 97
- PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLCRecruitingPhase 2Guangdong Association of Clinical TrialsNCT07416058Written as QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical CancerRecruitingPhase 2Xijing HospitalNCT07876154Written as Iparomlimab/Tuvonralimab
- Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction CancerRecruitingPhase 2Ruijin HospitalNCT07867392Written as Iparomlimab and Tuvonralimab (QL1706)
- Individualized Comprehensive Treatment for Advanced Hepatocellular CarcinomaRecruitingNot applicableNanjing Tianyinshan HospitalNCT06893887Written as QL1706
- HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICCRecruitingPhase 2Lianghe LuNCT07841574Written as hepatic arterial infusion chemotherapy (HAIC) combine with QL1706 and bevacizumab
- A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ AdenocarcinomaNot yet recruitingPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT07828873Written as Iparomlimab and Tuvonralimab Injection (QL1706)
- Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of RecurrenceRecruitingPhase 2Tongji HospitalNCT06954116Written as Iparomlimab and Tuvonralimab (QL1706)
- QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyNot yet recruitingPhase 2Hebei Medical University Fourth HospitalNCT07782840Written as Iparomlimab and Tuvonralimab (QL1706)
- Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular CarcinomaRecruitingPhase 2Hebei Medical University Fourth HospitalNCT07179900Written as QL1706
- Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine CarcinomaNot yet recruitingPhase 2West China HospitalNCT07738159Written as Iparomlimab and tuvonralimab injection (QL1706) + Lenvatinib + EP/EC
- QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract CancerRecruitingPhase 2Shanghai Zhongshan HospitalNCT07733115Written as Iparomlimab and Tuvonralimab (QL1706)
- FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRCNot yet recruitingPhase 3Sun Yat-sen UniversityNCT07729605Written as FOLFIRI + bevacizumab + QL1706
- SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular CarcinomaNot yet recruitingPhase 4Hebei Medical University Fourth HospitalNCT07668570Written as QL1706
- QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory StudyNot yet recruitingPhase 2Fujian Medical UniversityNCT07649473Written as QL1706 (Iparomlimab/Tuvonralimab)
- A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After ChemoradiotherapyRecruitingPhase 2Shanghai Chest HospitalNCT07091305Written as QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung CancerNot yet recruitingPhase 2/3Sun Yat-sen UniversityNCT07636226Written as QL1706
- Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With Microsatellite Instability/Mismatch Repair DeficiencyNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07595523Written as Iparomlimab/Tuvonralimab (QL1706)
- INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell CarcinomaRecruitingPhase 3Tongji HospitalNCT07002346Written as QL1706 (bispecific antibody targeting PD-1 and CTLA-4)
- QL1706 Plus Lenvatinib in Previously Treated Penile CancerRecruitingPhase 2Sun Yat-sen UniversityNCT07384416Written as QL1706 + Lenvatinib
- Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ AdenocarcinomaRecruitingPhase 2Qilu Hospital of Shandong UniversityNCT06932068Written as Iparomlimab and Tuvonralimab (QL1706)
See all 97 studies that test Iparomlimab/Tuvonralimab →
Given in every arm · 15 — Iparomlimab/Tuvonralimab is usual care beside what is tested
- A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral MelanomaNot yet recruitingPhase 4Peking University Cancer Hospital & InstituteNCT07854522Written as Iparomlimab and Tuvonralimab Injection (QL1706)
- Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.Not yet recruitingPhase 2Fudan UniversityNCT07829874Written as QL1706 (Iparomlimab/Tuvonralimab)
- Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor ThrombusRecruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07776080Written as Iparomlimab and Tuvonralimab (QL1706)
- Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical CancerRecruitingPhase 2Sun Yat-sen UniversityNCT07646301Written as Iparomlimab and Tuvonralimab (QL1706)
- Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort StudyNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07549906Written as Iparomlimab/Tuvonralimab
- A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal CancerNot yet recruitingPhase 2Huazhong University of Science and TechnologyNCT07502014Written as Iparomlimab and Tuvonralimab (QL1706)
- Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian CancerNot yet recruitingPhase 2Jiangsu Cancer Institute & HospitalNCT07407452Written as Iparomlimab and Tuvonralimab (QL1706)Injection
- Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid TumorsNot yet recruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT07272590Written as QL1706, IV infusion
- A Study of QLC5508 Combinations in Patients With Advanced Solid TumorsRecruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT07256782Written as QL1706
- A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBCRecruitingPhase 1Xijing HospitalNCT07178171Written as QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
- Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian CancerNot yet recruitingPhase 2Fudan UniversityNCT07117877Written as Iparomlimab and Tuvonralimab (QL1706)
- A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)Not yet recruitingPhase 2Anhui Provincial HospitalNCT07128251Written as Iparomlimab and Tuvonralimab Injection (QL1706)
- QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBCRecruitingPhase 2Fudan UniversityNCT06786026Written as QL1706
- QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRCRecruitingPhase 2Qilu Pharmaceutical Co., Ltd.NCT05799820Written as QL1706
- First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC PatientsActive, not recruitingPhase 2Fudan UniversityNCT06313970Written as QL1706